Advertisement

Neurochemical Research

, Volume 44, Issue 6, pp 1460–1474 | Cite as

Human Remyelination Promoting Antibody Stimulates Astrocytes Proliferation Through Modulation of the Sphingolipid Rheostat in Primary Rat Mixed Glial Cultures

  • Sara Grassi
  • Paola Giussani
  • Simona Prioni
  • Donald Button
  • Jing Cao
  • Irina Hakimi
  • Patrick Sarmiere
  • Maya Srinivas
  • Livia Cabitta
  • Sandro Sonnino
  • Alessandro PrinettiEmail author
Original Paper

Abstract

Remyelination promoting human IgMs effectively increase the number of myelinated axons in animal models of multiple sclerosis. Hence, they ultimately stimulate myelin production by oligodendrocytes (OLs); however, their exact mechanism of action remains to be elucidated, and in particular, it remains unclear whether they are directly targeting OLs, or their action is mediated by effects on other cell types. We assessed the effect of remyelination promoting antibody rHIgM22 on the proliferative response and on the ceramide/sphingosine 1-phosphate rheostat in mixed glial cell cultures (MGCs). rHIgM22 treatment caused a time-dependent increase in PDGFαR protein in MGCs. Forty-eight hours of treatment with rHIgM22 induced a dose-dependent proliferative response (evaluated as total cell number and as EdU(+) cell number) in MGCs. When the proliferation response of MGCs to rHIgM22 was analyzed as a function of the cell types, the most significant proliferative response was associated with GLAST(+) cells, i.e., astrocytes. In many cell types, the balance between different sphingolipid mediators (the “sphingolipid rheostat”), in particular ceramide and sphingosine 1-phosphate, is critical in determining the cell fate. rHIgM22 treatment in MGCs induced a moderate but significant inhibition of total acidic sphingomyelinase activity (measured in vitro on cell lysates), the main enzyme responsible for the stimulus-mediated production of ceramide, when treatment was performed in serum containing medium, but no significant differences were observed when antibody treatment was performed in the absence of serum. Moreover, rHIgM22 treatment, either in the presence or in absence of serum, had no effects on ceramide levels. On the other hand, rHIgM22 treatment for 24 h induced increased production and release of sphingosine 1-phosphate in the extracellular milieu of MGC. Release of sphingosine 1-phosphate upon rHIgM22 treatment was strongly reduced by a selective inhibitor of PDGFαR. Increased sphingosine 1-phosphate production does not seem to be mediated by regulation of the biosynthetic enzymes, sphingosine kinase 1 and 2, since protein levels of these enzymes and phosphorylation of sphingosine kinase 1 were unchanged upon rHIgM22 treatment. Instead, we observed a significant reduction in the levels of sphingosine 1-phosphate lyase 1, one of the key catabolic enzymes. Remarkably, rHIgM22 treatment under the same experimental conditions did not induce changes in the production and/or release of sphingosine 1-phosphate in pure astrocyte cultures. Taken together, these data suggest that rHIgM22 indirectly influences the proliferation of astrocytes in MGCs, by affecting the ceramide/sphingosine 1-phosphate balance. The specific cell population directly targeted by rHIgM22 remains to be identified, however our study unveils another aspect of the complexity of rHIgM22-induced remyelinating effect.

Keywords

rHIgM22 Multiple sclerosis Remyelination Sphingolipids 

Abbreviations

ASM

Acid sphingomyelinase

BSA

Bovine serum albumin

Cer

Ceramide

CNS

Central nervous system

CSF

Cerebrospinal fluid

MGCs

Mixed glial cultures

MS

Multiple sclerosis

OPCs

Oligodendrocyte precursor cells

SGPL1

Sphingosine 1-phosphate lyase 1

SK

Sphingosine kinase

SK1

Sphingosine kinase 1

SK2

Sphingosine kinase 2

SL

Sphingolipids

SM

Sphingomyelin

SMase

Sphingomyelinase

SPP1

Sphingosine 1-phosphate phosphatase 1

S1P

Sphingosine 1-phosphate

Notes

Acknowledgements

rHIgM22 and funding for this work was provided by Acorda Therapeutics, Inc., under a Research Agreement between University of Milano and Acorda Therapeutics (AP as the Principal Investigator). This study was partially supported by Piano di sostegno alla ricerca BIOMETRA—Linea B (Grant PSR2017_GIUSSANI) to PG. The funders had no role in study design, data collection, analysis and interpretation, decision to publish, or preparation of the manuscript and in the decision to submit the article for publication. AP is an Editor for Neurochemical Research.

References

  1. 1.
    Mayo L, Quintana FJ, Weiner HL (2012) The innate immune system in demyelinating disease. Immunol Rev 248:170–187CrossRefGoogle Scholar
  2. 2.
    Correale J, Farez MF (2015) The role of astrocytes in multiple sclerosis progression. Front Neurol 6:180CrossRefGoogle Scholar
  3. 3.
    Giunti D, Parodi B, Cordano C, Uccelli A, Kerlero de Rosbo N (2014) Can we switch microglia’s phenotype to foster neuroprotection? Focus on multiple sclerosis. Immunology 141:328–339CrossRefGoogle Scholar
  4. 4.
    Clemente D, Ortega MC, Melero-Jerez C, de Castro F (2013) The effect of glia-glia interactions on oligodendrocyte precursor cell biology during development and in demyelinating diseases. Front Cell Neurosci 7:268CrossRefGoogle Scholar
  5. 5.
    Zhang Y, Taveggia C, Melendez-Vasquez C, Einheber S, Raine CS, Salzer JL, Brosnan CF, John GR (2006) Interleukin-11 potentiates oligodendrocyte survival and maturation, and myelin formation. J Neurosci 26:12174–12185CrossRefGoogle Scholar
  6. 6.
    Omari KM, John G, Lango R, Raine CS (2006) Role for CXCR2 and CXCL1 on glia in multiple sclerosis. Glia 53:24–31CrossRefGoogle Scholar
  7. 7.
    Gudi V, Skuljec J, Yildiz O, Frichert K, Skripuletz T, Moharregh-Khiabani D, Voss E, Wissel K, Wolter S, Stangel M (2011) Spatial and temporal profiles of growth factor expression during CNS demyelination reveal the dynamics of repair priming. PLoS ONE 6:e22623CrossRefGoogle Scholar
  8. 8.
    Lampron A, Larochelle A, Laflamme N, Prefontaine P, Plante MM, Sanchez MG, Yong VW, Stys PK, Tremblay ME, Rivest S (2015) Inefficient clearance of myelin debris by microglia impairs remyelinating processes. J Exp Med 212:481–495CrossRefGoogle Scholar
  9. 9.
    Zorina Y, Stricker J, Caggiano AO, Button DC (2018) Human IgM antibody rHIgM22 promotes phagocytic clearance of myelin debris by microglia. Sci Rep 8:9392CrossRefGoogle Scholar
  10. 10.
    Miller LG Jr, Young JA, Ray SK, Wang G, Purohit S, Banik NL, Dasgupta S (2017) Sphingosine toxicity in EAE and MS: evidence for ceramide generation via serine-palmitoyltransferase activation. Neurochem Res 42:2755–2768CrossRefGoogle Scholar
  11. 11.
    Kim S, Steelman AJ, Zhang Y, Kinney HC, Li J (2012) Aberrant upregulation of astroglial ceramide potentiates oligodendrocyte injury. Brain Pathol 22:41–57CrossRefGoogle Scholar
  12. 12.
    Fischer I, Alliod C, Martinier N, Newcombe J, Brana C, Pouly S (2011) Sphingosine kinase 1 and sphingosine 1-phosphate receptor 3 are functionally upregulated on astrocytes under pro-inflammatory conditions. PLoS ONE 6:e23905CrossRefGoogle Scholar
  13. 13.
    Farez MF, Correale J (2016) Sphingosine 1-phosphate signaling in astrocytes: Implications for progressive multiple sclerosis. J Neurol Sci 361:60–65CrossRefGoogle Scholar
  14. 14.
    Groves A, Kihara Y, Chun J (2013) Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy. J Neurol Sci 328:9–18CrossRefGoogle Scholar
  15. 15.
    Warrington AE, Asakura K, Bieber AJ, Ciric B, Van Keulen V, Kaveri SV, Kyle RA, Pease LR, Rodriguez M (2000) Human monoclonal antibodies reactive to oligodendrocytes promote remyelination in a model of multiple sclerosis. Proc Natl Acad Sci USA 97:6820–6825CrossRefGoogle Scholar
  16. 16.
    Warrington AE, Bieber AJ, Ciric B, Pease LR, Van Keulen V, Rodriguez M (2007) A recombinant human IgM promotes myelin repair after a single, very low dose. J Neurosci Res 85:967–976CrossRefGoogle Scholar
  17. 17.
    Bieber AJ, Warrington A, Asakura K, Ciric B, Kaveri SV, Pease LR, Rodriguez M (2002) Human antibodies accelerate the rate of remyelination following lysolecithin-induced demyelination in mice. Glia 37:241–249CrossRefGoogle Scholar
  18. 18.
    Mullin AP, Cui C, Wang Y, Wang J, Troy E, Caggiano AO, Parry TJ, Colburn RW, Pavlopoulos E (2017) rHIgM22 enhances remyelination in the brain of the cuprizone mouse model of demyelination. Neurobiol Dis 105:142–155CrossRefGoogle Scholar
  19. 19.
    Cui C, Wang J, Mullin AP, Caggiano AO, Parry TJ, Colburn RW, Pavlopoulos E (2018) The antibody rHIgM22 facilitates hippocampal remyelination and ameliorates memory deficits in the cuprizone mouse model of demyelination. Brain Res 1694:73–86CrossRefGoogle Scholar
  20. 20.
    Watzlawik JO, Warrington AE, Rodriguez M (2013) PDGF is required for remyelination-promoting IgM stimulation of oligodendrocyte progenitor cell proliferation. PLoS ONE 8:e55149CrossRefGoogle Scholar
  21. 21.
    Prinetti A, Chigorno V, Prioni S, Loberto N, Marano N, Tettamanti G, Sonnino S (2001) Changes in the lipid turnover, composition, and organization, as sphingolipid-enriched membrane domains, in rat cerebellar granule cells developing in vitro. J Biol Chem 276:21136–21145CrossRefGoogle Scholar
  22. 22.
    Riboni L, Prinetti A, Bassi R, Tettamanti G (1994) Formation of bioactive sphingoid molecules from exogenous sphingomyelin in primary cultures of neurons and astrocytes. FEBS Lett 352:323–326CrossRefGoogle Scholar
  23. 23.
    McCarthy KD, de Vellis J (1980) Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue. J Cell Biol 85:890–902CrossRefGoogle Scholar
  24. 24.
    Riccitelli E, Giussani P, Di Vito C, Condomitti G, Tringali C, Caroli M, Galli R, Viani P, Riboni L (2013) Extracellular sphingosine-1-phosphate: a novel actor in human glioblastoma stem cell survival. PLoS ONE 8:e68229CrossRefGoogle Scholar
  25. 25.
    Cattaneo MG, Vanetti C, Samarani M, Aureli M, Bassi R, Sonnino S, Giussani P (2018) Cross-talk between sphingosine-1-phosphate and EGFR signaling pathways enhances human glioblastoma cell invasiveness. FEBS Lett 592:949–961CrossRefGoogle Scholar
  26. 26.
    Giussani P, Brioschi L, Bassi R, Riboni L, Viani P (2009) Phosphatidylinositol 3-kinase/AKT pathway regulates the endoplasmic reticulum to golgi traffic of ceramide in glioma cells: a link between lipid signaling pathways involved in the control of cell survival. J Biol Chem 284:5088–5096CrossRefGoogle Scholar
  27. 27.
    Riboni L, Viani P, Tettamanti G (2000) Estimating sphingolipid metabolism and trafficking in cultured cells using radiolabeled compounds. Methods Enzymol 311:656–682CrossRefGoogle Scholar
  28. 28.
    Bassi R, Anelli V, Giussani P, Tettamanti G, Viani P, Riboni L (2006) Sphingosine-1-phosphate is released by cerebellar astrocytes in response to bFGF and induces astrocyte proliferation through Gi-protein-coupled receptors. Glia 53:621–630CrossRefGoogle Scholar
  29. 29.
    Prinetti A, Basso L, Appierto V, Villani MG, Valsecchi M, Loberto N, Prioni S, Chigorno V, Cavadini E, Formelli F, Sonnino S (2003) Altered sphingolipid metabolism in N-(4-hydroxyphenyl)-retinamide-resistant A2780 human ovarian carcinoma cells. J Biol Chem 278:5574–5583CrossRefGoogle Scholar
  30. 30.
    Chami M, Halmer R, Schnoeder L, Anne Becker K, Meier C, Fassbender K, Gulbins E, Walter S (2017) Acid sphingomyelinase deficiency enhances myelin repair after acute and chronic demyelination. PLoS ONE 12:e0178622CrossRefGoogle Scholar
  31. 31.
    Becker KA, Halmer R, Davies L, Henry BD, Ziobro-Henry R, Decker Y, Liu Y, Gulbins E, Fassbender K, Walter S (2017) Blockade of experimental multiple sclerosis by inhibition of the acid sphingomyelinase/ceramide system. Neuro-Signals 25:88–97CrossRefGoogle Scholar
  32. 32.
    Pitson SM, Moretti PA, Zebol JR, Lynn HE, Xia P, Vadas MA, Wattenberg BW (2003) Activation of sphingosine kinase 1 by ERK1/2-mediated phosphorylation. EMBO J 22:5491–5500CrossRefGoogle Scholar
  33. 33.
    Leslie M (2015) Cleanup crew. Science 347:1058–1061CrossRefGoogle Scholar
  34. 34.
    Mitsunaga Y, Ciric B, Van Keulen V, Warrington AE, Paz Soldan M, Bieber AJ, Rodriguez M, Pease LR (2002) Direct evidence that a human antibody derived from patient serum can promote myelin repair in a mouse model of chronic-progressive demyelinating disease. FASEB J 16:1325–1327CrossRefGoogle Scholar
  35. 35.
    Howe CL, Bieber AJ, Warrington AE, Pease LR, Rodriguez M (2004) Antiapoptotic signaling by a remyelination-promoting human antimyelin antibody. Neurobiol Dis 15:120–131CrossRefGoogle Scholar
  36. 36.
    Wright BR, Warrington AE, Edberg DD, Rodriguez M (2009) Cellular mechanisms of central nervous system repair by natural autoreactive monoclonal antibodies. Arch Neurol 66:1456–1459CrossRefGoogle Scholar
  37. 37.
    Pirko I, Ciric B, Gamez J, Bieber AJ, Warrington AE, Johnson AJ, Hanson DP, Pease LR, Macura SI, Rodriguez M (2004) A human antibody that promotes remyelination enters the CNS and decreases lesion load as detected by T2-weighted spinal cord MRI in a virus-induced murine model of MS. FASEB J 18:1577–1579CrossRefGoogle Scholar
  38. 38.
    Watzlawik J, Holicky E, Edberg DD, Marks DL, Warrington AE, Wright BR, Pagano RE, Rodriguez M (2010) Human remyelination promoting antibody inhibits apoptotic signaling and differentiation through Lyn kinase in primary rat oligodendrocytes. Glia 58:1782–1793CrossRefGoogle Scholar
  39. 39.
    Paz Soldan MM, Warrington AE, Bieber AJ, Ciric B, Van Keulen V, Pease LR, Rodriguez M (2003) Remyelination-promoting antibodies activate distinct Ca2 + influx pathways in astrocytes and oligodendrocytes: relationship to the mechanism of myelin repair. Mol Cell Neurosci 22:14–24CrossRefGoogle Scholar
  40. 40.
    Silberstein FC, De Simone R, Levi G, Aloisi F (1996) Cytokine-regulated expression of platelet-derived growth factor gene and protein in cultured human astrocytes. J Neurochem 66:1409–1417CrossRefGoogle Scholar
  41. 41.
    Cuvillier O, Pirianov G, Kleuser B, Vanek PG, Coso OA, Gutkind S, Spiegel S (1996) Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature 381:800–803CrossRefGoogle Scholar
  42. 42.
    Zhang H, Desai NN, Olivera A, Seki T, Brooker G, Spiegel S (1991) Sphingosine-1-phosphate, a novel lipid, involved in cellular proliferation. J Cell Biol 114:155–167CrossRefGoogle Scholar
  43. 43.
    Obeid LM, Linardic CM, Karolak LA, Hannun YA (1993) Programmed cell death induced by ceramide. Science 259:1769–1771CrossRefGoogle Scholar
  44. 44.
    Olivera A, Spiegel S (1993) Sphingosine-1-phosphate as second messenger in cell proliferation induced by PDGF and FCS mitogens. Nature 365:557–560CrossRefGoogle Scholar
  45. 45.
    Chudakova DA, Zeidan YH, Wheeler BW, Yu J, Novgorodov SA, Kindy MS, Hannun YA, Gudz TI (2008) Integrin-associated Lyn kinase promotes cell survival by suppressing acid sphingomyelinase activity. J Biol Chem 283:28806–28816CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Sara Grassi
    • 1
  • Paola Giussani
    • 1
  • Simona Prioni
    • 1
  • Donald Button
    • 2
  • Jing Cao
    • 2
  • Irina Hakimi
    • 2
  • Patrick Sarmiere
    • 2
  • Maya Srinivas
    • 2
  • Livia Cabitta
    • 1
  • Sandro Sonnino
    • 1
  • Alessandro Prinetti
    • 1
    Email author
  1. 1.Department of Medical Biotechnology and Translational MedicineUniversity of MilanMilanItaly
  2. 2.Acorda Therapeutics, Inc.ArdsleyUSA

Personalised recommendations